Results 171 to 180 of about 34,485 (247)

Effects of a Selective Cannabinoid CB2 Agonist and Antagonist on Intravenous Nicotine Self Administration and Reinstatement of Nicotine Seeking

, 2012
Islam Gamaleddin, A. M. Zvonok, Alexandros Makriyannis, Steven R. Goldberg, Bernard Le Foll   +4 more
openalex   +2 more sources

Relative efficacy of GLP‐1 and GLP‐1/GIP receptor agonists in the prevention of alcohol‐use disorders using a target trial emulation approach

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 137-150, January 2026.
Abstract Aims There is growing evidence that the GLP‐1 system is implicated in alcohol and other substance use disorders, and that GLP‐1‐based therapies may have therapeutic relevance in alcohol use disorder (AUD). We aimed to determine the impact of GLP‐1 based therapies on incident AUDs in a real‐world setting in patients with T2D.
Alex E. Henney, David R. Riley, Megan Heague, Carl A. Roberts, Theresa J. Hydes, Matthew Anson, David M. Hughes, Uazman Alam, Daniel J. Cuthbertson   +8 more
wiley   +1 more source

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial (SYNCHRONIZE™‐1)

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 337-346, January 2026.
Abstract Aims Survodutide, a novel glucagon receptor and glucagon‐like peptide‐1 (GLP‐1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report
Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Psychiatric effects of GLP‐1 receptor agonists: A systematic review of emerging evidence

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 50-59, January 2026.
Abstract This systematic review examines the current literature on glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs)‐associated psychiatric manifestations, including depression, suicidality, eating disorders, substance use disorders (SUD) and schizophrenia spectrum disorders.
Brianna Sa, Anthony Maristany, Ashwin Subramaniam, Ryan Guillen, Brooke Buonocore, Audrey Smith, Sean E. Oldak, Vanessa Padilla   +7 more
wiley   +1 more source

Discovery of Highly Potent and Selective α4β2-Nicotinic Acetylcholine Receptor (nAChR) Partial Agonists Containing an Isoxazolylpyridine Ether Scaffold that Demonstrate Antidepressant-like Activity. Part II

, 2012
Li-Fang Yu, J. Brek Eaton, Allison Fedolak, Han-Kun Zhang, Taleen Hanania, Dani Brunner, Ronald J. Lukas, Alan P. Kozikowski   +7 more
openalex   +2 more sources

A positive allosteric modulator of α7 nAChRs augments neuroprotective effects of endogenous nicotinic agonists in cerebral ischaemia [PDF]

, 2013
Bopanna I. Kalappa, Fen Sun, Stephen R. Johnson, Kunlin Jin, Victor V. Uteshev   +4 more
openalex   +1 more source

Use of Psychoactive Substances Before Incarceration Among Prison Inmates With Drug Abuse or Dependence: Data From the OPPIDUM Program

Fundamental &Clinical Pharmacology, Volume 40, Issue 1, January 2026.
ABSTRACT Background The objective of this study was to assess the prevalence of dependence and abuse of psychoactive substances (PAS) among prison inmates, using data from the OPPIDUM program between 2013 and 2022. Methods OPPIDUM is an annual, cross‐sectional national program, conducted among users consulting in specialised addiction centres.
Zeinab Abbas, Clémence Lacroix, Elisabeth Jouve, Céline Eiden, Joelle Micallef, Hélène Peyrière, and the French Addictovigilance network, Alexandre Peyre, Reynald Leboisselier, Celian Bertin, Nathalie Fouilhe, Anne‐Sylvie Caous, Johan Thiery, Marylène Guerlais, Lauriane Charuel, Stéphanie Pain, Emilie Jouanjus   +16 more
wiley   +1 more source

The α7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain [PDF]

, 2016
Deniz Bağdaş, Jenny L. Wilkerson, Abhijit Kulkarni, Wisam Toma, Shakir D. AlSharari, Zülfiye Gül, Aron H. Lichtman, Roger L. Papke, Ganesh A. Thakur, M. Imad Damaj   +9 more
openalex   +1 more source

The ATP-mediated cytokine release by macrophages is down-modulated by unconventional α9* nicotinic acetylcholine receptors. [PDF]

Front Immunol
Wolf PMK, Hanke D, Singh VK, Keller HL, Ettischer LJ, Teppe L, Amati AL, Hecker A, Husain-Syed F, Rohde M, Nuber UA, Büttner K, McIntosh JM, Liese J, Mazurek S, Grau V, Richter K.   +16 more
europepmc   +1 more source

Relationships of agonist properties to the single channel kinetics of nicotinic acetylcholine receptors

, 1988
Roger L. Papke, Glenn L. Millhauser, Zoe R. Lieberman, Robert E. Oswald   +3 more
openalex   +1 more source